PLUS1
5.215
-0.125 (-2.34%)
-0.125 (-2.34%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Pro
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.125 | -2.34% | 5.215 | 4.65 | 5.90 | 5.43 | 5.34 | 16:59:04 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 5.14 | 5.35 | 0.21 | 3.93% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,847 | 8,690,082 | $ 5.2785 | $ 45,870,846 | 7,455,338 | 0.261 - 10.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:06:19 | average | 290,000 | $ 4.9975 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.82B | 541.03M | 302.11M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 9.23M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 7/08/2020 | 17:07 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 7/08/2020 | 16:31 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/19/2020 | 17:19 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 6/08/2020 | 19:24 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 6/08/2020 | 17:28 | Edgar (US Regulatory) | Proxy Soliciting Materials (revised) (prer14a) |
| 6/08/2020 | 06:02 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting.. |
| 6/02/2020 | 17:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.14 | 7.25 | 4.65 | 5.85 | 9,593,992 | -1.93 | -26.96% |
| 1 Month | 2.99 | 10.01 | 2.90 | 5.73 | 11,443,799 | 2.23 | 74.41% |
| 3 Months | 2.39 | 10.01 | 2.11 | 4.41 | 7,466,056 | 2.83 | 118.2% |
| 6 Months | 0.859 | 10.01 | 0.79 | 3.19 | 6,648,902 | 4.36 | 507.1% |
| 1 Year | 0.4136 | 10.01 | 0.261 | 2.82 | 3,820,781 | 4.80 | 1,160.88% |
| 3 Years | 0.77 | 10.01 | 0.0552 | 2.52 | 1,478,764 | 4.45 | 577.27% |
| 5 Years | 0.83 | 10.01 | 0.0552 | 2.37 | 978,000 | 4.39 | 528.31% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
